Financial News

My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

1.210 -0.250 (-17.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 Next >
53 Biggest Movers From Yesterday
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 91.2% to settle at $0.6980 on Wednesday. ION Geophysical was awarded a five-year contract by Brunei Shell Petroleum... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday. AlloVir, Inc. (NASDAQ: ALVR) shares climbed 39% to $7.52... 
Via Benzinga
Why Is Lexaria Bioscience (LEXX) Stock Up Today?
Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares. 
Via InvestorPlace
Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Results From Hypertension Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
51 Biggest Movers From Thursday
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Why Lexaria Shares Are Rising Today
 
Via Benzinga
Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Begins Nicotine Formulation Creation, Evaluation Program
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Aims To Demonstrate DehydraTECH's Performance In Epilepsy Research
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Bioscience's 24th Patent Sets Stage For Market Opportunities In Australia
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
Lexaria Bioscience Optimistic About Upcoming Hypertension Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
Lexaria's IP Portfolio Grows Following Receipt Of 24th Granted Patent
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received a new patent entitled “Compositions... 
Via Benzinga
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Bioscience Receives Award For Oral Nicotine Compound Patent
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a... 
Via Benzinga
Studies Advance Lexaria Bioscience's Tech For Improving Pharmaceutical Drugs
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience is dedicated to... 
Via Benzinga
Lexaria's DehydraTECH(TM) Demonstrates Faster Delivery Of Sildenafil
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)... 
Via Benzinga
Lexaria Bioscience Optimistic Of Positive Study Results
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
Lexaria Optimistic About Expanded DehydraTECH Investigations
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria just announced ground-breaking... 
Via Benzinga
Lexaria World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
Photo by Shelby Ireland on Unsplash 
Via Benzinga
Following Sildenafil Study, Lexaria Announces Plans For More Studies In 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria’s animal study could be... 
Via Benzinga
Lexaria's DehydraTECH(TM) To Be Evaluated As Treatment For Multiple Conditions
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)... 
Via Benzinga
Lexaria Technology Shows Promise In Improving Performance Of ED Drugs
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Health and wellness drug bio-... 
Via Benzinga
Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. In 2021, Lexaria conducted several main studies evaluating... 
Via Benzinga
Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. 
Via Benzinga
Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Chris Bunka, the Chairman and CEO of Lexaria, featured on the... 
Via Benzinga
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review... 
Via Benzinga
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback